Shukui Qin, MD, PhD

Transarterial Chemoembolization with Durvalumab or Durvalumab + Bevacizumab in Patients with Locoregional Hepatocellular Carcinoma: EMERALD-1

Purpose: Because curative therapy is not always feasible and there is no standard systemic therapy, patients with intermediate-stage hepatocellular carcinoma (HCC) are treated with locore...

Shukui Qin , MD, PhD;

Zhenggang Ren ;

Joseph Erinjeri ;

Shethah Morgan ;

Gordon Cohen ;

Yasuaki Arai , MD;

Riccardo Lencioni , MD;

Bruno Sangro , MD, PhD;

Stephen Lam Chan , MD;

Masatoshi Kudo , MD, PhD;

10/21/2019

CIO 2020-4 Transarterial Chemoembolization Combined With Durvalumab±Bevacizumab in Patients With Locoregional HCC (EMERALD-1)

Yasuaki Arai , MD;

Zhenggang Ren ;

Joseph Erinjeri ;

Philip He ;

Shethah Morgan ;

Gordon Cohen ;

Riccardo Lencioni , MD;

Bruno Sangro , MD, PhD;

Masatoshi Kudo , MD, PhD;

Stephen Lam Chan , MD;

Shukui Qin , MD, PhD;

07/23/2021

CIO 2023-13 IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab vs surveillance in hepatocellular carcinoma patients

Purpose: The risk of HCC recurrence after liver resection or ablation with curative intent is 70-80% within 5 years, indicating an unmet need for effective adjuvant therapies. Atezolizuma...

Jeong Heo , MD, PhD;

David Hsieh , MD;

Masatoshi Kudo , MD, PhD;

Han Chu Lee , MD, PhD;

Qinshu Lian , PhD;

Shinichiro Nakamura , MD, PhD;

Kazushi Numata , MD;

Shukui Qin , MD, PhD;

Jessica Spahn , PhD;

Won Young Tak , MD, PhD;

Thomas Uguen , MD;

Edward Cha , PhD;